NEW YORK (360Dx) – The US Food and Drug Administration has given de novo clearance of Baebies' Seeker platform for quantitatively measuring the activity of lysosomal enzymes α-L-iduronidase, α-D-glucosidase, β-glucocerebrosidase, and α-D-galactosidase A from newborn dried blood spot specimens, the company said recently.

Reduced activity of these enzymes may suggest lysosomal storage diseases (LSD) mucopolysaccharidosis type 1, Pompe, Gaucher, or Fabry, Baebies said. It added that Seeker is the only FDA-authorized test on the market for LSDs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.